All USA USA Territories: American Samoa (USA); Guam (USA); Puerto Rico (USA); Virgin Islands (USA); Northern Mariana Islands (USA); USA Compact Free Associations:The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA) Canada:Alberta; British Columbia; Manitoba; New Brunswick; Newfoundland and Labrador; Northwest Territories; Nova Scotia; Nunavut; Ontario; Prince Edward Island; Quebec; Saskatchewan; Yukon; International, Israel and Canada.
Grants to USA, Canada, and International investigators affiliated with institutions for endocrinology research. Eligible research addresses medical concerns caused by imbalances in growth hormones. Funding is intended to improve patient outcomes in the clinical area of short stature/growth failure. Research projects that will be considered for Pfizer support will advance the medical knowledge of short stature.
Projects submitted may include:
Morbidities in growth disorders
Strategies to evaluate and treat growth disorders including Quality of Life and Patient Reported Outcomes
Comparative pathophysiology of daily vs long-acting growth hormone
Evaluation of adherence of daily and long-acting growth hormone treatment
Novel strategies to address current unmet medical needs in short stature management which could be addressed with long-acting growth hormone treatment
Comparison of clinical effects of daily vs long-acting growth hormone
Projects may include basic, translational, or clinical research
(Note for clinical research studies requesting drug supply: Drug supply refers only to those countries where a drug has regulatory marketing authorization and commercial stock supply is available).
Others (see text field entitled "Additional Eligibility Criteria" for clarification)
Additional Eligibility Criteria
Only organizations are eligible to receive grants.
- The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
- Applicant must be affiliated with a host institution.
Geographic Scope: Global
- The institution and principal investigator (PI) must be based in one of the eligible countries noted above.
Pfizer believes that every person deserves to be seen, heard, and cared for, and they work to further this goal by encouraging grant requestors with different backgrounds, perspectives, and experiences to apply.
Individuals and medical practice groups are not eligible to apply.
Any proposal submitted with a commercialization component will be considered out of scope and not reviewed.
The following topics fall outside of the scope of the Competitive Grant Program:
- Support for ongoing clinical programs that are part of an organization’s routine operations
- Proposals that do not focus on listed strategies for each therapeutic area except as specified in the RFP posting.
Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar).
It should be noted that grants awarded through GMG cannot be used to purchase Pfizer therapeutic agents (prescription or nonprescription).
Pre-Application Information
Key Dates:
- RFP release date: 13 September 2022
- Grant Application due date: 13 February 2023
- Anticipated Grant Award Notification Date: April 2023
- Anticipated Project Start and End Dates: on or after October 2023
Applicants may be asked for additional clarification during the review period.
Number of Grants
Pfizer anticipates awarding a minimum of 2 projects.
Estimated Size of Grant
Individual projects requesting up to $150,000 will be considered.
Term of Contract
Projects typically last one to two years.
Anticipated Project Start and End Dates: on or after October 2023
If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com), with the subject line “2023 RD G - Growth Hormone Research”
